Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

BCL2-Related Ovarian Killer (BOK) (N-Term) Peptid

BOK Reaktivität: Human Wirt: Synthetic BP, WB
Produktnummer ABIN5512172

Kurzübersicht für BCL2-Related Ovarian Killer (BOK) (N-Term) Peptid (ABIN5512172)

Target

BOK (BCL2-Related Ovarian Killer (BOK))

Spezies

Human

Quelle

  • 2
Synthetic

Applikation

Blocking Peptide (BP), Western Blotting (WB)
  • Protein Region

    N-Term

    Sequenz

    AAEIMDAFDR SPTDKELVAQ AKALGREYVH ARLLRAGLSW SAPERAAPVP

    Produktmerkmale

    This is a synthetic peptide designed for use in combination with anti-BOK Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target

    BOK (BCL2-Related Ovarian Killer (BOK))

    Hintergrund

    The protein encoded by this gene belongs to the BCL2 family, members of which form homo- or heterodimers, and act as anti- or proapoptotic regulators that are involved in a wide variety of cellular processes. Studies in rat show that this protein has restricted expression in reproductive tissues, interacts strongly with some antiapoptotic BCL2 proteins, not at all with proapoptotic BCL2 proteins, and induces apoptosis in transfected cells. Thus, this protein represents a proapoptotic member of the BCL2 family.

    Alias Symbols: BOK,BCL2L9,

    Protein Size: 212

    Gen-ID

    666

    NCBI Accession

    XP_005247094

    UniProt

    Q9UMX3
Sie sind hier:
Chat with us!